MATCHING FOR PRIVATE OR PUBLIC HLA EPITOPES REDUCES ACUTE REJECTION EPISODES AND IMPROVES 2-YEAR RENAL-ALLOGRAFT FUNCTION

Citation
Rm. Mckenna et al., MATCHING FOR PRIVATE OR PUBLIC HLA EPITOPES REDUCES ACUTE REJECTION EPISODES AND IMPROVES 2-YEAR RENAL-ALLOGRAFT FUNCTION, Transplantation, 66(1), 1998, pp. 38-43
Citations number
38
Categorie Soggetti
Transplantation,Surgery,Immunology
Journal title
ISSN journal
00411337
Volume
66
Issue
1
Year of publication
1998
Pages
38 - 43
Database
ISI
SICI code
0041-1337(1998)66:1<38:MFPOPH>2.0.ZU;2-I
Abstract
Background. The current role of HLA matching in renal transplantation is controversial. Public HLA epitope matching has been suggested to be as advantageous as private HLA matching, with the added benefit of in creasing recipients' access to well-matched grafts. Methods. In this s ingle center study of 105 renal transplant recipients, we examined the association of HLA matching with early (0-3 months) and late (4-6 mon ths) rejection episodes (RE), as well as renal allograft function up t o 2 years after transplant. Results. Poor HLA-DR, but not HLA-A or -B, matching was associated with early RE (0 DR matches, RE=2.7+/-0.19, 1 DR match, RE=2.37+/-0.18, vs, 2 DR matches, RE=1.5+0.38; P<0.01), In contrast, poor HLA-B, but not HLA-A or -DR, matching was associated wi th late rejections (0 HLA-B matches, RE=1.1+/-0.51 vs. 1-2 HLA-B match es, RE=0.5+/-0.1; P<0,004), HLA-B matching was also associated with a significantly lower serum creatinine (SCr) level at 24 months (0 HLA-B matches, SCr=178+/-20 mu mol/L vs. SCr=132+/-6 mu mol/L for 1-2 HLA-B matches; P<0.025), Matching for 10 supertypic HLA-A and -B crossreact ive groups was associated with reduced late graft rejection (0-2 resid ue matches, RE=1.15+/-0.18 vs. RE=0.62+/-0.12 for 3 to 7 residue match es; P<0.013) as well as a significantly lower SCr level at 24 months ( 0-2 residue matches, SCr=205+/-29 mu mol/L vs SCr=131+/-6 mu mol/L for 3 to 7 residue matches; P<0,001) after transplantation. Conclusions. HLA-DR matching was associated with a reduced frequency of early rejec tion episodes, whereas HLA-B or residue/cross-reactive group matching was associated with a reduced frequency of late rejection episodes and improved graft function at 2 years.